A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 Dec 2017 Planned End Date changed from 15 May 2019 to 15 Jun 2019.
- 04 Dec 2017 Planned primary completion date changed from 15 Dec 2018 to 15 Jan 2019.